Lupin Founder's Legacy Chronicled in New Book Highlighting India's Pharma Rise
Event summary
- Book 'Made in India' launched on February 9, 2026, detailing Lupin's founder Desh Bandhu Gupta's journey and India's pharma industry growth.
- Lupin now operates 15 manufacturing sites and 7 research centers globally, serving over 120 markets.
- Panel discussion featured pharma leaders including Dilip Shanghvi (Sun Pharma) and Dr. Yusuf Hamied (Cipla).
- Lupin's foundation has impacted over 2.02 million beneficiaries across 5,400 villages in India.
The big picture
The book launch underscores India's transformation into a global pharma powerhouse, with Lupin playing a pivotal role. This strategic narrative could enhance Lupin's brand value and attractiveness to investors, especially as the industry faces increasing competition and regulatory challenges. The panel discussion highlighted the collaborative efforts of Indian pharma leaders in elevating the country's soft and hard power in healthcare.
What we're watching
- Industry Leadership
- How Lupin will leverage this narrative to strengthen its position against competitors like Sun Pharma and Cipla.
- Global Expansion
- The pace at which Lupin can expand its manufacturing and research capabilities to meet growing global demand.
- Regulatory Compliance
- Whether Lupin can maintain its strong regulatory standing amid increasing scrutiny of Indian pharma manufacturers.
Related topics